Long-term cost-effectiveness using a Markov model (MM)
Crohn’s, ulcerative colitis
APPENDIX, ULCERATIVE COLITIS
A Markov model (Appendix A total of 56% UC patients in the trial were without a colectomy at the last follow-up, and the number (%) of colectomies in trial patients at different follow-up time points is shown in Appendix There was no reported mortality in one of the treatment arms of the CONSTRUCT trial. The study accounted for the impact of within-trial mortality in the cost-effectiveness DT model. For long-term modelling in the Markov model, the study considered 3-year mortality data from a published observational study conducted in England for ulcerative colitis and Crohn’s patients during 1998–2003 [